IGF2BP家族在人类疾病中的研究进展
Research Progress of the IGF2BP Family in Human Diseases
DOI: 10.12677/acm.2026.1641628, PDF,   
作者: 朱欣怡, 赵 丽*:中国药科大学基础医学与临床药学学院公共实验平台,江苏 南京
关键词: IGF2BPsm6A癌症神经系统疾病代谢类疾病IGF2BPS m6A Cancer Neurological Diseases Metabolic Diseases
摘要: N6-甲基腺苷化(m6A)是真核生物RNA中最普遍的表观遗传修饰,通过调控RNA的翻译或稳定性来影响基因的表达和表型变化。胰岛素样生长因子-2-mRNA结合蛋白家族(IGF2BPs)主要作为m6A效应蛋白发挥作用,通过维持目的RNA的稳定性来影响后续基因的表达。IGF2BPs被广泛认为在癌症、代谢类疾病和神经系统疾病的发生和发展中起着举足轻重的作用。因此,IGF2BPs在临床应用方面有着不可估量的潜力。在这篇综述中,本人讨论了IGF2BPs作为m6A阅读器的功能和机制,以及IGF2BPs在人类疾病治疗中的研究进展与治疗潜力,以望为之后的疾病早期筛查、诊断和预后的临床研究提供新的思路。
Abstract: N6-methyladenosine modification (m6A) is the most common epigenetic modification in eukaryotic RNA, which affects gene expression and phenotypic changes by regulating RNA translation or stability. The insulin-like growth factor-2-mRNA binding protein family (IGF2BPs) mainly functions as m6A effector proteins, influencing subsequent gene expression by maintaining the stability of the target RNA. IGF2BPs are widely regarded as playing a crucial role in the occurrence and development of cancer, metabolic diseases, and neurological disorders. Therefore, IGF2BPs have considerable potential for clinical applications. In this review, I discuss the functions and mechanisms of IGF2BPs as m6A readers, as well as the research progress and therapeutic potential of IGF2BPs in the treatment of human diseases, in the hope of providing new ideas for future clinical studies on early screening, diagnosis, and prognosis of diseases.
文章引用:朱欣怡, 赵丽. IGF2BP家族在人类疾病中的研究进展[J]. 临床医学进展, 2026, 16(4): 3638-3651. https://doi.org/10.12677/acm.2026.1641628

参考文献

[1] Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A.H., Wewer, U.M. and Nielsen, F.C. (1999) A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development. Molecular and Cellular Biology, 19, 1262-1270. [Google Scholar] [CrossRef] [PubMed]
[2] Bell, J.L., Wächter, K., Mühleck, B., Pazaitis, N., Köhn, M., Lederer, M., et al. (2013) Insulin-Like Growth Factor 2 mRNA-Binding Proteins (IGF2BPs): Post-Transcriptional Drivers of Cancer Progression? Cellular and Molecular Life Sciences, 70, 2657-2675. [Google Scholar] [CrossRef] [PubMed]
[3] Wächter, K., Köhn, M., Stöhr, N. and Hüttelmaier, S. (2013) Subcellular Localization and RNP Formation of IGF2BPs (IGF2 mRNA-Binding Proteins) Is Modulated by Distinct RNA-Binding Domains. Biological Chemistry, 394, 1077-1090. [Google Scholar] [CrossRef] [PubMed]
[4] Nielsen, J. (2004) Sequential Dimerization of Human Zipcode-Binding Protein IMP1 on RNA: A Cooperative Mechanism Providing RNP Stability. Nucleic Acids Research, 32, 4368-4376. [Google Scholar] [CrossRef] [PubMed]
[5] Huang, H., Weng, H., Sun, W., Qin, X., Shi, H., Wu, H., et al. (2018) Recognition of RNA N6-Methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation. Nature Cell Biology, 20, 285-295. [Google Scholar] [CrossRef] [PubMed]
[6] Lederer, M., Bley, N., Schleifer, C. and Hüttelmaier, S. (2014) The Role of the Oncofetal IGF2 mRNA-Binding Protein 3 (IGF2BP3) in Cancer. Seminars in Cancer Biology, 29, 3-12. [Google Scholar] [CrossRef] [PubMed]
[7] Ren, Z., Zhao, S. and Zou, P. (2025) Deciphering the RNA Landscape of RNA Granules. Biochemistry, 64, 3156-3164. [Google Scholar] [CrossRef] [PubMed]
[8] Du, Q., Zhu, Z. and Pei, D. (2021) The Biological Function of IGF2BPs and Their Role in Tumorigenesis. Investigational New Drugs, 39, 1682-1693. [Google Scholar] [CrossRef] [PubMed]
[9] Ryu, Y., Chang, E., Park, H., Cho, S. and An, J. (2025) Proteogenomic Analysis on RNA m6A Modification-Associated Genes Identifies a Distinct Subgroup with High IGF2BPs Expression across Cancer Types. International Journal of Medical Sciences, 22, 3815-3827. [Google Scholar] [CrossRef
[10] Dai, N. (2020) The Diverse Functions of IMP2/IGF2BP2 in Metabolism. Trends in Endocrinology & Metabolism, 31, 670-679. [Google Scholar] [CrossRef] [PubMed]
[11] Deng, Y., Zhu, H., Xiao, L., Liu, C., Liu, Y. and Gao, W. (2021) Identification of the Function and Mechanism of m6A Reader IGF2BP2 in Alzheimer’s Disease. Aging, 13, 24086-24100. [Google Scholar] [CrossRef] [PubMed]
[12] Li, X., Guo, W., Wen, Y., Meng, C., Zhang, Q., Chen, H., et al. (2025) Structural Basis for the RNA Binding Properties of Mouse IGF2BP3. Structure, 33, 771-785.e3. [Google Scholar] [CrossRef] [PubMed]
[13] Korn, S.M., Ulshöfer, C.J., Schneider, T. and Schlundt, A. (2021) Structures and Target RNA Preferences of the RNA-Binding Protein Family of IGF2BPs: An Overview. Structure, 29, 787-803. [Google Scholar] [CrossRef] [PubMed]
[14] Peixoto, P., Cartron, P., Serandour, A.A. and Hervouet, E. (2020) From 1957 to Nowadays: A Brief History of Epigenetics. International Journal of Molecular Sciences, 21, Article 7571. [Google Scholar] [CrossRef] [PubMed]
[15] Yang, C., Hu, Y., Zhou, B., Bao, Y., Li, Z., Gong, C., et al. (2020) The Role of m6A Modification in Physiology and Disease. Cell Death & Disease, 11, Article No. 960. [Google Scholar] [CrossRef] [PubMed]
[16] Vasilopoulou, A., Kalafati, E., Drakopoulou, E. and Anagnou, N.P. (2025) m6A mRNA Methylation in Hematopoiesis: The Importance of Writing, Erasing, and Reading. Cells, 14, Article 1388. [Google Scholar] [CrossRef
[17] Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., et al. (2014) A METTL3-METTL14 Complex Mediates Mammalian Nuclear RNA N6-Adenosine Methylation. Nature Chemical Biology, 10, 93-95. [Google Scholar] [CrossRef] [PubMed]
[18] Yang, Y., Hsu, P.J., Chen, Y. and Yang, Y. (2018) Dynamic Transcriptomic m6A Decoration: Writers, Erasers, Readers and Functions in RNA Metabolism. Cell Research, 28, 616-624. [Google Scholar] [CrossRef] [PubMed]
[19] Müller, S., Glaß, M., Singh, A.K., Haase, J., Bley, N., Fuchs, T., et al. (2019) IGF2BP1 Promotes SRF-Dependent Transcription in Cancer in a m6A-and miRNA-Dependent Manner. Nucleic Acids Research, 47, 375-390. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, L., Wan, Y., Zhang, Z., Jiang, Y., Gu, Z., Ma, X., et al. (2021) IGF2BP1 Overexpression Stabilizes PEG10 mRNA in an m6A-Dependent Manner and Promotes Endometrial Cancer Progression. Theranostics, 11, 1100-1114. [Google Scholar] [CrossRef] [PubMed]
[21] Wu, H., Ding, X., Hu, X., Zhao, Q., Chen, Q., Sun, T., et al. (2022) LINC01021 Maintains Tumorigenicity by Enhancing N6-Methyladenosine Reader IMP2 Dependent Stabilization of MSX1 and JARID2: Implication in Colorectal Cancer. Oncogene, 41, 1959-1973. [Google Scholar] [CrossRef] [PubMed]
[22] Huo, F., Xie, M., Zhu, Z., Zheng, J. and Pei, D. (2022) SHMT2 Promotes the Tumorigenesis of Renal Cell Carcinoma by Regulating the m6A Modification of PPAT. Genomics, 114, Article ID: 110424. [Google Scholar] [CrossRef] [PubMed]
[23] Cheng, Y., Gao, Z., Zhang, T., Wang, Y., Xie, X., Han, G., et al. (2023) Decoding m6A RNA Methylome Identifies PRMT6-Regulated Lipid Transport Promoting AML Stem Cell Maintenance. Cell Stem Cell, 30, 69-85.e7. [Google Scholar] [CrossRef] [PubMed]
[24] Hu, Y., Gong, C., Li, Z., Liu, J., Chen, Y., Huang, Y., et al. (2022) Demethylase ALKBH5 Suppresses Invasion of Gastric Cancer via PKMYT1 m6A Modification. Molecular Cancer, 21, Article No. 34. [Google Scholar] [CrossRef] [PubMed]
[25] Su, C., Zhang, Y., Chen, P., Yang, W., Du, J. and Zhang, D. (2022) Methyltransferase-like 3 Induces the Development of Cervical Cancer by Enhancing Insulin-Like Growth Factor 2 mRNA-Binding Proteins 3-Mediated Apoptotic Chromatin Condensation Inducer 1 mRNA Stability. Bioengineered, 13, 7034-7048. [Google Scholar] [CrossRef] [PubMed]
[26] Yu, Y., Lv, D., Wang, C., Song, X., Xie, T., Wang, T., et al. (2022) Hsa_circ_0003258 Promotes Prostate Cancer Metastasis by Complexing with IGF2BP3 and Sponging miR-653-5p. Molecular Cancer, 21, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
[27] Gu, Y., Niu, S., Wang, Y., Duan, L., Pan, Y., Tong, Z., et al. (2021) DMDRMR-Mediated Regulation of m6A-Modified CDK4 by m6A Reader IGF2BP3 Drives ccRCC Progression. Cancer Research, 81, 923-934. [Google Scholar] [CrossRef] [PubMed]
[28] Cai, M., Liu, H., Shao, C., Li, T., Jin, J., Liang, Y., et al. (2025) Metabolomics and Metabolites in Cancer Diagnosis and Treatment. Molecular Biomedicine, 6, Article No. 109. [Google Scholar] [CrossRef
[29] Yang, J., Shay, C., Saba, N.F. and Teng, Y. (2024) Cancer Metabolism and Carcinogenesis. Experimental Hematology & Oncology, 13, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[30] Byun, J. (2023) Tumor Lactic Acid: A Potential Target for Cancer Therapy. Archives of Pharmacal Research, 46, 90-110. [Google Scholar] [CrossRef] [PubMed]
[31] Ananieva, E.A., Powell, J.D. and Hutson, S.M. (2016) Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond. Advances in Nutrition, 7, 798S-805S. [Google Scholar] [CrossRef] [PubMed]
[32] Xiao, Y., Yang, Y., Xiong, H. and Dong, G. (2024) The Implications of FASN in Immune Cell Biology and Related Diseases. Cell Death & Disease, 15, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[33] Demicco, M., Liu, X., Leithner, K. and Fendt, S. (2024) Metabolic Heterogeneity in Cancer. Nature Metabolism, 6, 18-38. [Google Scholar] [CrossRef] [PubMed]
[34] Colhado Rodrigues, B.L., Lallo, M.A. and Perez, E.C. (2020) The Controversial Role of Autophagy in Tumor Development: A Systematic Review. Immunological Investigations, 49, 386-396. [Google Scholar] [CrossRef] [PubMed]
[35] Shen, C., Xuan, B., Yan, T., Ma, Y., Xu, P., Tian, X., et al. (2020) m6A-Dependent Glycolysis Enhances Colorectal Cancer Progression. Molecular Cancer, 19, Article No. 72. [Google Scholar] [CrossRef] [PubMed]
[36] Weng, H., Huang, F., Yu, Z., Chen, Z., Prince, E., Kang, Y., et al. (2022) The m6A Reader IGF2BP2 Regulates Glutamine Metabolism and Represents a Therapeutic Target in Acute Myeloid Leukemia. Cancer Cell, 40, 1566-1582.e10. [Google Scholar] [CrossRef] [PubMed]
[37] Xu, Y., Zhou, J., Li, L., Yang, W., Zhang, Z., Zhang, K., et al. (2022) FTO-Mediated Autophagy Promotes Progression of Clear Cell Renal Cell Carcinoma via Regulating SIK2 mRNA Stability. International Journal of Biological Sciences, 18, 5943-5962. [Google Scholar] [CrossRef] [PubMed]
[38] Wang, Q., Chen, C., Ding, Q., Zhao, Y., Wang, Z., Chen, J., et al. (2020) METTL3-Mediated m6A Modification of HDGF mRNA Promotes Gastric Cancer Progression and Has Prognostic Significance. Gut, 69, 1193-1205. [Google Scholar] [CrossRef] [PubMed]
[39] Jiang, L., Li, Y., He, Y., Wei, D., Yan, L. and Wen, H. (2021) Knockdown of m6A Reader IGF2BP3 Inhibited Hypoxia-Induced Cell Migration and Angiogenesis by Regulating Hypoxia Inducible Factor-1α in Stomach Cancer. Frontiers in Oncology, 11, Article 711207. [Google Scholar] [CrossRef] [PubMed]
[40] Hendrix, M.J.C., Seftor, E.A., Seftor, R.E.B., Chao, J., Chien, D. and Chu, Y. (2016) Tumor Cell Vascular Mimicry: Novel Targeting Opportunity in Melanoma. Pharmacology & Therapeutics, 159, 83-92. [Google Scholar] [CrossRef] [PubMed]
[41] Liu, X., He, H., Zhang, F., Hu, X., Bi, F., Li, K., et al. (2022) m6A Methylated EphA2 and VEGFA through IGF2BP2/3 Regulation Promotes Vasculogenic Mimicry in Colorectal Cancer via PI3K/AKT and ERK1/2 Signaling. Cell Death & Disease, 13, Article No. 483. [Google Scholar] [CrossRef] [PubMed]
[42] Wan, W., Ao, X., Chen, Q., Yu, Y., Ao, L., Xing, W., et al. (2022) METTL3/IGF2BP3 Axis Inhibits Tumor Immune Surveillance by Upregulating N6-Methyladenosine Modification of PD-L1 mRNA in Breast Cancer. Molecular Cancer, 21, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[43] Wei, J., Yin, Y., Zhou, J., Chen, H., Peng, J., Yang, J., et al. (2020) METTL3 Potentiates Resistance to Cisplatin through m6A Modification of TFAP2C in Seminoma. Journal of Cellular and Molecular Medicine, 24, 11366-11380. [Google Scholar] [CrossRef] [PubMed]
[44] Li, T., Hu, P., Zuo, Z., Lin, J., Li, X., Wu, Q., et al. (2019) METTL3 Facilitates Tumor Progression via an m6A-IGF2BP2-Dependent Mechanism in Colorectal Carcinoma. Molecular Cancer, 18, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[45] Li, H., Huang, G., Tu, J., Lv, D., Jin, Q., Chen, J., et al. (2022) METTL14-Mediated Epitranscriptome Modification of MN1 mRNA Promote Tumorigenicity and All-Trans-Retinoic Acid Resistance in Osteosarcoma. eBioMedicine, 82, Article ID: 104142. [Google Scholar] [CrossRef] [PubMed]
[46] Tatekawa, S., Tamari, K., Chijimatsu, R., Konno, M., Motooka, D., Mitsufuji, S., et al. (2022) N6-Methyladenosine Methylation-Regulated Polo-Like Kinase 1 Cell Cycle Homeostasis as a Potential Target of Radiotherapy in Pancreatic Adenocarcinoma. Scientific Reports, 12, Article No. 11074. [Google Scholar] [CrossRef] [PubMed]
[47] Yang, Z.M., Zhao, F.Q., Gu, X.F., Feng, L.X., Xu, M.S., Li, T., et al. (2021) Binding of RNA m6A by IGF2BP3 Triggers Chemo-Resistance of HCT8 Cells Via Upregulation of ABCB1. American Journal of Cancer Research, 11, 1428-1445.
[48] Tang, Z., Cao, J., Yao, J., Fan, X., Zhao, J., Zhao, M., et al. (2023) KDM1A-Mediated Upregulation of METTL3 Ameliorates Alzheimer’s Disease via Enhancing Autophagic Clearance of P-Tau through m6A-Dependent Regulation of STUB1. Free Radical Biology and Medicine, 195, 343-358. [Google Scholar] [CrossRef] [PubMed]
[49] Miller, C., Ealy, A., Gregory, A., Janarthanam, C., Albers, W., Richardson, G., et al. (2025) Pathological α-Synuclein Dysregulates Epitranscriptomic Writer METTL3 to Drive Neuroinflammation in Microglia. Cell Reports, 44, Article ID: 115618. [Google Scholar] [CrossRef] [PubMed]
[50] Jingrui, W., Haihui, Y., Jinjin, Y. and Le, F. (2025) IGF2BP2 Regulates the Progression of Alzheimer’s Disease through m6A‐Mediated NLRP3 Inflammasome. Immunity, Inflammation and Disease, 13, e70121. [Google Scholar] [CrossRef] [PubMed]
[51] Yu, Z., Huang, L., Xia, Y., Cheng, S., Yang, C., Chen, C., et al. (2022) Analysis of m6A Modification Regulators in the Substantia Nigra and Striatum of MPTP-Induced Parkinson’s Disease Mice. Neuroscience Letters, 791, Article ID: 136907. [Google Scholar] [CrossRef] [PubMed]
[52] Gong, X., Huang, M. and Chen, L. (2024) nrf1 Mitigates Motor Dysfunction and Dopamine Neuron Degeneration in Mice with Parkinson’s Disease by Promoting GLRX m6A Methylation through Upregulation of METTL3 Transcription. CNS Neuroscience & Therapeutics, 30, e14441. [Google Scholar] [CrossRef] [PubMed]
[53] Wang, Q., Xie, S., Yang, K., Guo, Y., Huang, H., Li, S., et al. (2026) Histone Lactylation Contributes to Neuropathic Pain by Facilitating m6A Reader Protein IGF2BP2 Expression in DRG Sensory Neurons. The Journal of Neuroscience, 46, e0365252025. [Google Scholar] [CrossRef
[54] Elssaig, E.H., Ahmed‐Abakur, E.H., Alnour, T.M.S., Alsubai, M.A., Ali, A.E., Ullah, M.F., et al. (2025) Significant Association between Genetic Polymorphism of Insulin‐like Growth Factor‐2 mRNA Binding Protein‐2 and Type 2 Diabetes Mellitus: A Population‐Based Case-Control Study. Journal of Clinical Laboratory Analysis, 39, e25147. [Google Scholar] [CrossRef] [PubMed]
[55] Elssaig, E.H., Ahmed-Abakur, E.H., Alnour, T.M.S., Alsubai, M.A. and Yousif, A. (2024) Significant Association between Insulin-Like Growth Factor 2 mRNA-Binding Protein 2, Interleukin-6 Polymorphisms, and Type 2 Diabetes Mellitus. Journal of Research in Medical Sciences, 29, 71. [Google Scholar] [CrossRef] [PubMed]
[56] Yang, R., Wang, X., Zhang, Y., Jin, L., Zhao, K., Chen, J., et al. (2025) Genetic Variations in IGF2BP2 and CAPN10 and Their Interaction with Environmental Factors Increase Gestational Diabetes Mellitus Risk in Chinese Women. Gene, 941, Article ID: 149226. [Google Scholar] [CrossRef] [PubMed]
[57] Rattanapan, Y., Nongwa, K., Supanpong, C., Satsadeedat, C., Sai-ong, T., Kooltheat, N., et al. (2024) Downregulation of miR-25-3p and Its Impact on PTAFR and IGF2BP3 Expression in Type 2 Diabetes Mellitus: Implications for Biomarker Discovery and Disease Pathogenesis. Journal of Clinical Medicine Research, 16, 536-546. [Google Scholar] [CrossRef] [PubMed]
[58] Regué, L., Zhao, L., Ji, F., Wang, H., Avruch, J. and Dai, N. (2021) RNA m6A Reader IMP2/IGF2BP2 Promotes Pancreatic β-Cell Proliferation and Insulin Secretion by Enhancing PDX1 Expression. Molecular Metabolism, 48, Article ID: 101209. [Google Scholar] [CrossRef] [PubMed]
[59] Alvarez-Dominguez, J.R., Winther, S., Hansen, J.B., Lodish, H.F. and Knoll, M. (2022) An Adipose LncRAP2-Igf2bp2 Complex Enhances Adipogenesis and Energy Expenditure by Stabilizing Target mRNAs. iScience, 25, Article ID: 103680. [Google Scholar] [CrossRef] [PubMed]
[60] Luo, S., Sun, Y., Hu, Y. and Xu, Y. (2025) Lactylation-Induced ALKBH5 Targets RNF123 to Worsen Retinal Müller Cell Activation through PKM2-Regulated Glycolysis in Diabetic Retinopathy. Journal of Translational Medicine, 23, Article No. 105. [Google Scholar] [CrossRef
[61] Liang, A., Liu, J., Wei, Y., Liao, Y., Wu, F., Ruan, J., et al. (2023) m6A Reader IGF2BP1 Accelerates Apoptosis of High Glucose-Induced Vascular Endothelial Cells in a m6A-HMGB1 Dependent Manner. PeerJ, 11, e14954. [Google Scholar] [CrossRef] [PubMed]
[62] Wang, T., Li, X., Tao, Y., Wang, X., Li, L. and Liu, J. (2024) METTL3-Mediated NDUFB5 m6A Modification Promotes Cell Migration and Mitochondrial Respiration to Promote the Wound Healing of Diabetic Foot Ulcer. Journal of Translational Medicine, 22, Article No. 643. [Google Scholar] [CrossRef] [PubMed]
[63] Jiang, L., Liu, X., Hu, X., Gao, L., Zeng, H., Wang, X., et al. (2022) METTL3-Mediated m6A Modification of TIMP2 mRNA Promotes Podocyte Injury in Diabetic Nephropathy. Molecular Therapy, 30, 1721-1740. [Google Scholar] [CrossRef] [PubMed]
[64] Yao, Q., Chen, Y., Zhang, X., Wang, L., Li, J., Lv, J., et al. (2025) Decoding m6A RNA Methylation in Kidney Disorders: From Molecular Insights to Therapeutic Strategies. Journal of Translational Medicine, 23, Article No. 771. [Google Scholar] [CrossRef] [PubMed]
[65] Jiang, Y., Peng, J., Song, J., He, J., Jiang, M., Wang, J., et al. (2021) Loss of Hilnc Prevents Diet-Induced Hepatic Steatosis through Binding of IGF2BP2. Nature Metabolism, 3, 1569-1584. [Google Scholar] [CrossRef] [PubMed]
[66] Wang, P., Wang, X., He, D. and Zhuang, C. (2023) LncRNA AK142643 Promotes Hepatic Lipid Accumulation by Upregulating CD36 via Interacting with IGF2BP2. Gene, 887, Article ID: 147747. [Google Scholar] [CrossRef] [PubMed]
[67] Lu, Y., Qie, D., Yang, F. and Wu, J. (2023) LncRNA MEG3 Aggravates Adipocyte Inflammation and Insulin Resistance by Targeting IGF2BP2 to Activate TLR4/NF-κB Signaling Pathway. International Immunopharmacology, 121, Article ID: 110467. [Google Scholar] [CrossRef] [PubMed]
[68] Kuai, D., Zhu, S., Shi, H., Yang, R., Liu, T., Liu, H., et al. (2021) Aberrant Expression of m6A mRNA Methylation Regulators in Colorectal Adenoma and Adenocarcinoma. Life Sciences, 273, Article ID: 119258. [Google Scholar] [CrossRef] [PubMed]
[69] Du, J., Ji, H., Ma, S., Jin, J., Mi, S., Hou, K., et al. (2021) m6A Regulator-Mediated Methylation Modification Patterns and Characteristics of Immunity and Stemness in Low-Grade Glioma. Briefings in Bioinformatics, 22, bbab013. [Google Scholar] [CrossRef] [PubMed]
[70] Liu, J., Li, Z., Cheang, I., Li, J. and Zhou, C. (2022) RNA-Binding Protein IGF2BP1 Associated with Prognosis and Immunotherapy Response in Lung Adenocarcinoma. Frontiers in Genetics, 13, Article 777399. [Google Scholar] [CrossRef] [PubMed]
[71] Wang, X., Guan, D., Wang, D., Liu, H., Wu, Y., Gong, W., et al. (2021) Genetic Variants in m6A Regulators Are Associated with Gastric Cancer Risk. Archives of Toxicology, 95, 1081-1088. [Google Scholar] [CrossRef] [PubMed]
[72] Hu, X., Peng, W., Zhou, H., Jiang, J., Zhou, X., Huang, D., et al. (2020) IGF2BP2 Regulates DANCR by Serving as an N6-Methyladenosine Reader. Cell Death & Differentiation, 27, 1782-1794. [Google Scholar] [CrossRef] [PubMed]
[73] Lu, S., Han, L., Hu, X., Sun, T., Xu, D., Li, Y., et al. (2021) N6-Methyladenosine Reader IMP2 Stabilizes the ZFAS1/OLA1 Axis and Activates the Warburg Effect: Implication in Colorectal Cancer. Journal of Hematology & Oncology, 14, Article No. 188. [Google Scholar] [CrossRef] [PubMed]
[74] Wang, Y., Lu, J., Wu, Q., Jin, Y., Wang, D., Chen, Y., et al. (2025) Correction: LncRNA LINRIS Stabilizes IGF2BP2 and Promotes the Aerobic Glycolysis in Colorectal Cancer. Molecular Cancer, 24, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
[75] Li, Y., Gu, J., Xu, F., Zhu, Q., Chen, Y., Ge, D., et al. (2021) Molecular Characterization, Biological Function, Tumor Microenvironment Association and Clinical Significance of m6A Regulators in Lung Adenocarcinoma. Briefings in Bioinformatics, 22, bbaa225. [Google Scholar] [CrossRef] [PubMed]
[76] Li, Y., Xiao, J., Bai, J., Tian, Y., Qu, Y., Chen, X., et al. (2019) Molecular Characterization and Clinical Relevance of m6A Regulators across 33 Cancer Types. Molecular Cancer, 18, Article No. 137. [Google Scholar] [CrossRef] [PubMed]
[77] Lv, B., Li, L., Liu, M. and Zou, S. (2026) Circular RNAs in Cancer Immunology: Immune Escape, Therapeutic Resistance, and Nanomedicine Synergies. Translational Oncology, 63, Article ID: 102631. [Google Scholar] [CrossRef
[78] Cui, J., Zhu, Y., Liu, X., Wang, W., Jiang, X., Xia, Y., et al. (2022) Comprehensive Analysis of N6-Methyladenosine Regulators with the Tumor Immune Landscape and Correlation between the Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 and Programmed Death Ligand 1 in Bladder Cancer. Cancer Cell International, 22, Article No. 72. [Google Scholar] [CrossRef] [PubMed]
[79] Tong, Y., Li, S., Shen, L., Yan, L., Zhu, Z. and Hua, Q. (2025) Multi-Omics and Experimental Validation Identify Methylation-Related Genes and METTL16 as Key Regulators in Diabetic Foot Ulcer Pathogenesis. Scientific Reports, 15, Article No. 42334. [Google Scholar] [CrossRef
[80] Liao, S., Zhang, L., Shi, L., Hu, H., Gu, Y., Wang, T., et al. (2025) Integrating Bulk and Single-Cell RNA Sequencing Data: Unveiling RNA Methylation and Autophagy-Related Signatures in Chronic Obstructive Pulmonary Disease Patients. Scientific Reports, 15, Article No. 4005. [Google Scholar] [CrossRef] [PubMed]